Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Operating Leases: 2020-2025

Historic Operating Leases for BridgeBio Pharma (BBIO) over the last 6 years, with Sep 2025 value amounting to $8.7 million.

  • BridgeBio Pharma's Operating Leases rose 49.51% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 49.51%. This contributed to the annual value of $4.7 million for FY2024, which is 47.71% down from last year.
  • BridgeBio Pharma's Operating Leases amounted to $8.7 million in Q3 2025, which was up 116.67% from $4.0 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Operating Leases high stood at $18.7 million for Q3 2021, and its period low was $4.0 million during Q2 2025.
  • In the last 3 years, BridgeBio Pharma's Operating Leases had a median value of $8.3 million in 2024 and averaged $7.7 million.
  • In the last 5 years, BridgeBio Pharma's Operating Leases soared by 126.85% in 2021 and then crashed by 47.71% in 2024.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Operating Leases stood at $17.4 million in 2021, then fell by 29.57% to $12.3 million in 2022, then dropped by 26.83% to $9.0 million in 2023, then tumbled by 47.71% to $4.7 million in 2024, then surged by 49.51% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q3 2025, $4.0 million for Q2 2025, and $4.9 million during Q1 2025.